Structural Biotech Challenges: Legal Disputes, Regulatory Pressures, and Innovation Gaps
Original framing: “STAT+: The biotech news you need to read today” — STAT News
Rare disease patients, especially those from low-income and minority communities, are often excluded from clinical trials and decision-making processes. Their lived experiences are critical to shaping equitable biotech policies.
The current biotech landscape is shaped by a convergence of corporate interests, regulatory inertia, and underfunded public research.
To move toward a more equitable and innovative future, we must integrate open-source models, community-led research, and cross-cultural perspectives. Historical patterns show that public investment and regulatory reform can drive progress, but only when aligned with the needs of marginalized communities. By embracing a systemic view that includes scientific rigor, artistic empathy, and indigenous wisdom, we can create a biotech ecosystem that serves all people, not just the profitable few.